WSAAI 2024 61st Annual Scientific Session

Koloa, HI US
February 4, 2024 to February 8, 2024

The Western Society of Allergy Asthma & Immunology (WSAAI) consistently delivers high-quality, scientific lectures in the field of Allergy & Clinical Immunology in a unique format promoting attendee interaction with some of the foremost researchers and clinicians in our specialty.  Such conferences have been our notable achievement for over five decades. Among the subjects covered in the upcoming program address various topics around asthma such as Asthma Phenotyping, management of childhood asthma, biologic therapy for asthma; Food Allergen Immunotherapy and new and emerging therapies for food allergy; Chronic cough and cough hypersensitivity and trials and tribulations in chronic cough.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Western Society of Allergy Asthma & Immunology (WSAAI).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 20 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 20 contact hours.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this activity, learners should be able to…

1. Summarize the relative efficacy of biologic therapies for the treatment of asthma and describe immune pathways that may indicate responsiveness to several of these therapies.  

2. Demonstrate a broad knowledge of food allergen therapies in the development or approval pipeline, including potential application into clinical practice in the future.

3. Describe the mechanisms underlying chronic cough.

4. Identify patients with suspected mast cell disorders who should have additional workup for potential targeted treatment.

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 20.00 AMA PRA Category 1 Credit™
  • 20.00 Attendance
  • 20.00 CBRN
Course opens: 
Course expires: 
Event starts: 
02/04/2024 - 3:00pm CST
Event ends: 
02/08/2024 - 5:45pm CST
Grand Hyatt Kauai
1571 Poipu Road
Koloa, HI 96756
United States

All relevant financial relationships with ineligible companies have been mitigated.

Kimberly G. Blumenthal, MD, MSc, Speaker
Independent contractor – Thermofisher Scientific

Mark Boguniewicz, MD, Speaker
Advisor – AbbVie, Amgen, Dermavant, Eli Lilly, Janssen, Incyte, Leo Pharma, Pfizer, Regeneron, Sanofi Genzyme
Independent contractor – Incyte, Regeneron, Sanofi Genzyme

Noam A. Cohen, MD, PhD, Speaker
Advisor – GSK, Sanofi/Regeneron
Independent contractor – GeneOne Life Sciences
Royalties/patent beneficiary – GeneOne Life Sciences

David Elkayam, MD, Planner, Moderator
Consultant – Siva
Researcher – Allergy Therapeutics, AstraZeneca, Bellus Health, Genentech, Novartis, Siva, Suzhou

Stacie M. Jones, MD, Speaker
Advisor – Aimmune
Researcher – Aimmune, ALK-Abello, Aravax PTY, DBV Technologies, Genentech, Regeneron
Research advisory board – Regeneron

Lorcan McGarvey, MD, FRCP
Advisor – AstraZeneca, Chiesi, GSK, Merck
Speaker – AstraZeneca, Chiesi, GSK, Merck
Consultant – Genentech, Nocion Therapeutics

Joshua Milner, MD, Speaker
Advisor – Blueprint Medicines

Marc Riedl, MD, MS, Planner
Consultant – Astria, BioCryst, Biomarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, KalVista, Pfizer, Pharming, Pharvaris, Sanofi/Regeneron, Takeda
Researcher – BioCryst, Biomarin, CSL Behring, Ionis, KalVista, Pharvaris, Takeda
Speaker – CSL Behring, Grifols, Pharming, Takeda

Stanley Szefler, MD, Speaker
Advisor – Moderna
Consultant – AstraZeneca, GSK, OM Pharma, Regeneron, Sanofi
Researcher – Eli Lilly, Propeller Health

Amy Wagelie-Steffen, MD, Planner
Advisor – BioCryst, Pharming
Consultant – BioCryst, Pharming
Speaker – Amgen, AstraZeneca, Genentech, Sanofi/Regeneron

Sally E. Wenzel, MD, Speaker
Advisor – Aer Therapeutics
Researcher – Pieris, Regeneron
Stocks – Aer Therapeutics

Andrew White, MD, Planner, Moderator
Advisor – Amgen, AstraZeneca, Blueprint, Cogent, GSK, Optinose, Sanofi/Regeneron
Researcher – AstraZeneca, Sanofi/Regeneron
Speaker – AstraZeneca, Blueprint, GSK, Optinose, Sanofi/Regeneron

The following have no relevant financial relationships with ineligible companies to disclose:

Matthew C. Altman, MD, Speaker

Amy Klion, MD, Speaker

René Anderson-Cowell, MD, Planner, Moderator

Steven Machtinger, MD, Planner, Moderator

Jinny Chang, MD, Planner

Karol Anderson, Planner


Available Credit

  • 20.00 AMA PRA Category 1 Credit™
  • 20.00 Attendance
  • 20.00 CBRN
Please login or create an account to take this course.